Analysts Set Expectations for HOWL Q3 Earnings

Key Points

• Leerink Partners has forecasted Werewolf Therapeutics' Q3 2025 earnings per share (EPS) at ($0.36), with a full-year estimate of ($1.56) EPS.
• Five analysts currently rate the stock as a "Buy," with an average target price of $8.00, despite recent downgrades from other analysts.
• Werewolf Therapeutics reported a loss of ($0.40) EPS in its last quarter, exceeding the consensus estimate by $0.10.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Werewolf Therapeutics in a research note issued on Wednesday, September 3rd. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings of ($0.36) per share for the quarter. The consensus estimate for Werewolf Therapeutics' current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Werewolf Therapeutics' Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($2.04) EPS and FY2029 earnings at ($0.98) EPS.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.10.

HOWL has been the subject of several other research reports. Citigroup reissued a "buy" rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. JMP Securities decreased their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 21st. Finally, Bank of America decreased their price target on Werewolf Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Monday, August 25th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $8.00.

Werewolf Therapeutics Price Performance

NASDAQ:HOWL remained flat at $1.43 during trading hours on Monday. The company's stock had a trading volume of 171,173 shares, compared to its average volume of 145,677. Werewolf Therapeutics has a 52-week low of $0.60 and a 52-week high of $4.18. The company has a current ratio of 5.30, a quick ratio of 5.30 and a debt-to-equity ratio of 0.60. The company's fifty day simple moving average is $1.29 and its 200 day simple moving average is $1.14. The stock has a market capitalization of $65.39 million, a PE ratio of -0.87 and a beta of 0.64.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. D. E. Shaw & Co. Inc. purchased a new stake in shares of Werewolf Therapeutics in the 4th quarter valued at about $26,000. Quadrature Capital Ltd purchased a new stake in Werewolf Therapeutics during the second quarter valued at $28,000. Vontobel Holding Ltd. bought a new stake in Werewolf Therapeutics during the first quarter valued at about $34,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the second quarter worth about $48,000. Finally, Nuveen LLC bought a new position in Werewolf Therapeutics during the first quarter valued at approximately $71,000. Institutional investors own 64.84% of the company's stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.